<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:media="http://search.yahoo.com/mrss/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Plunges &#8211; USA NEWS LIVE</title>
	<atom:link href="https://bloggingthree.soflytech.com/tag/plunges/feed/" rel="self" type="application/rss+xml" />
	<link>https://bloggingthree.soflytech.com</link>
	<description>All About USA NEWS</description>
	<lastBuildDate>Wed, 05 Jun 2024 09:46:29 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://bloggingthree.soflytech.com/wp-content/uploads/2024/04/cropped-THE-USA1-e1713184454543-1-32x32.png</url>
	<title>Plunges &#8211; USA NEWS LIVE</title>
	<link>https://bloggingthree.soflytech.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Pharmaceutical giant GSK plunges 9% after US court allows scientific testimony in Zantac lawsuit</title>
		<link>https://bloggingthree.soflytech.com/2024/06/pharmaceutical-giant-gsk-plunges-9-after-us-court-allows-scientific-testimony-in-zantac-lawsuit/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Wed, 05 Jun 2024 09:46:29 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[giant]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[lawsuit]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Plunges]]></category>
		<category><![CDATA[scientific]]></category>
		<category><![CDATA[testimony]]></category>
		<category><![CDATA[Zantac]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=5452</guid>

					<description><![CDATA[LONDON — Shares of the British pharmaceutical giant GSK fell 9% on Monday after a U.S. court ruled that scientific evidence could possibly be presented to advance a series of lawsuits related to the discontinued heartburn drug Zantac. The Delaware state court ruled late Friday that plaintiffs&#39; experts can testify in roughly 75,000 cases alleging [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="RegularArticle-ArticleBody-5" data-module="ArticleBody" data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p>LONDON — Shares of the British pharmaceutical giant <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-1">GSK<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    fell 9% on Monday after a U.S. court ruled that scientific evidence could possibly be presented to advance a series of lawsuits related to the discontinued heartburn drug Zantac.</p>
<p>The Delaware state court ruled late Friday that plaintiffs&#39; experts can testify in roughly 75,000 cases alleging that the once-popular drug ranitidine &#8211; sold within the U.S. under the brand name Zantac &#8211; could cause cancer.</p>
<p>&#8220;This case has always been about bringing the science before a jury,&#8221; Brent Wisner, an attorney on the Wisner Baum law firm that represents most of the plaintiffs, said in a press release.</p>
<p>The dispute has been simmering for years and involves quite a few pharmaceutical firms. Zantac was sold as a prescription drug by GSK within the Nineteen Eighties before becoming an over-the-counter drug. After the patent expired within the Nineteen Nineties, it was sold by firms corresponding to the French <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-3">Sanofi<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>the US company Pfizer and the German company Boehringer Ingelheim.</p>
<p>The drug was withdrawn <a href="https://www.rcpch.ac.uk/news-events/news/medicine-safety-alert-ranitidine-withdrawn#:~:text=Ranitidine%20products%20(Brand%20names%20including,ranitidine%20medicines%20in%20the%20EU." target="_blank" rel="noopener">European</a> And <a href="https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market" target="_blank" rel="noopener">US</a> markets in 2019 and 2020 after regulators conducted a security review that raised concerns that it contained a probable carcinogen called NDMA.</p>
<p>The firms involved deny that there&#8217;s a scientific consensus that the drug may be linked to the later development of cancer.</p>
<p>GSK said in a press release on Friday that the corporate disagrees with the recent ruling in Delaware and can immediately appeal.</p>
</div>
<div role="region" aria-labelledby="Placeholder-ArticleBody-Video-107417623">
<div role="button" tabindex="0" id="Placeholder-ArticleBody-Video-107417623" class="PlaceHolder-wrapper" data-vilynx-id="7000340823" data-test="VideoPlaceHolder">
<div class="InlineVideo-videoEmbed" id="InlineVideo-0" data-test="InlineVideo">
<div class="InlineVideo-wrapper">
<div class="InlineVideo-inlineThumbnailContainer"><img decoding="async" class="InlineVideo-videoThumbnail" src="https://image.cnbcfm.com/api/v1/image/107417624-17162781881716278185-34619448332-1080pnbcnews.jpg?v=1716278187&#038;w=750&#038;h=422&#038;vtcrop=y" alt="AstraZeneca is in its ‘post-Covid era’ as the company will launch 20 new drugs by 2030, according to its CFO"><span class="InlineVideo-videoButton"></span><span></span></div>
</div>
</div>
</div>
</div>
<div class="group">
<p>It said the choice contradicted the federal court&#39;s December 2022 ruling within the multi-district litigation hearing that dismissed all five cancer claims. It added that the court&#39;s decision only addressed whether the methodology utilized by the plaintiffs&#39; experts was reliable enough to be presented as evidence at trial.</p>
<p>&#8220;After 16 epidemiological studies examining data on ranitidine use in humans, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of cancer,&#8221; GSK said.</p>
<p>While nearly all of cases happen in Delaware, a smaller variety of cases are brought against various firms in California, Illinois and Pennsylvania.</p>
<p>Analysts at Jefferies had pointed to a possible tailwind for GSK at the tip of May after a jury within the US state of Illinois present in the primary Zantac case to go to court that GSK and Boehringer Ingelheim weren&#8217;t answerable for the colon cancer.</p>
<p>GSK, the corporate most affected by the cases, could face settlement costs of between one and greater than three billion dollars, in keeping with a variety of analyst reports. <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-shares-tumble-9-after-70000-zantac-lawsuits-allowed-move-forward-2024-06-03/" target="_blank" rel="noopener">quoted by</a> ^ &#8220;Reuters&#8221;.</p>
<p>Sanofi, which is known as in around 25,000 of the 75,000 lawsuits, expressed disappointment in its own statement on Friday in regards to the decision to not exclude the plaintiffs&#39; experts from the lawsuits and announced that it might also appeal. Sanofi shares were 1 percent lower on Monday.</p>
<p>Pfizer told CNBC on Monday that the corporate was involved in &#8220;a portion&#8221; of the Delaware cases and had resolved a &#8220;significant number&#8221; of cases by which it was named as a defendant.</p>
<p>&#8220;While we have great sympathy for the plaintiffs in these cases, there is no reliable scientific evidence that Zantac, which has been reviewed and approved by the FDA, causes cancer. Pfizer has not sold a Zantac product for more than 15 years and has done so only for a limited period of time, nor has Pfizer ever manufactured a Zantac product,&#8221; the corporate said in a press release.</p>
<p>The Financial Times <a href="https://www.ft.com/content/9f59da60-4441-42c4-b84c-6de0c3931d08" target="_blank" rel="noopener">reported last month</a> that Pfizer has agreed to pay between $200 million and $250 million to settle greater than 10,000 Zantac lawsuits. CNBC has not independently confirmed the quantity.</p>
<p>CNBC has asked Boehringer Ingelheim for comment.</p>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/107364701-17062137262020-10-26t134955z_622340489_rc2dqj98d9sj_rtrmadp_0_gsk-results.jpeg?v=1706213775&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
		<item>
		<title>Sam Altman&#039;s Oklo Plunges 54% in NYSE Debut After SPAC</title>
		<link>https://bloggingthree.soflytech.com/2024/05/sam-altmans-oklo-plunges-54-in-nyse-debut-after-spac/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Fri, 10 May 2024 22:25:36 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[Altman39s]]></category>
		<category><![CDATA[Debut]]></category>
		<category><![CDATA[NYSE]]></category>
		<category><![CDATA[Oklo]]></category>
		<category><![CDATA[Plunges]]></category>
		<category><![CDATA[Sam]]></category>
		<category><![CDATA[SPAC]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=3129</guid>

					<description><![CDATA[Sam Altman is now chairman of a public company. But it&#39;s not OpenAI. On Friday, the corporate Oklo, which makes a speciality of modern nuclear fission, began trading on the New York Stock Exchange. The company, which has not yet generated any revenue, was acquired through a special purpose acquisition company (SPAC) called AltC Acquisition [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div>
<p>Sam Altman is now chairman of a public company.  But it&#39;s not OpenAI.</p>
<p>On Friday, the corporate Oklo, which makes a speciality of modern nuclear fission, began trading on the New York Stock Exchange.  The company, which has not yet generated any revenue, was acquired through a special purpose acquisition company (SPAC) called AltC Acquisition Corp. founded and run by Altman.  to the stock market.</p>
<p>Under the ticker symbol “<span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-2">OK<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>“Shares plunged 54% to $8.45 on Friday, valuing the company at about $364 million.  According to a, Oklo received gross proceeds of approximately $306 million from the transaction <a href="https://www.businesswire.com/news/home/20240510464172/en/Oklo-Inc.-Begins-Trading-on-the-New-York-Stock-Exchange" target="_blank" rel="noopener">release</a>.</p>
<p>Oklo&#39;s business model is based on the commercialization of nuclear fission, the reaction that powers all nuclear power plants.  Instead of traditional reactors, the company wants to use mini-nuclear reactors housed in A-frame structures.  Their goal is to sell the energy to end consumers <a href="https://www.canarymedia.com/articles/nuclear/nuclear-startup-oklo-looks-to-rebound-with-backing-from-sam-altman" target="_blank" rel="noopener">US Air Force</a> and large technology companies.</p>
<p>Oklo is currently working on building its first small reactor in Idaho, which could eventually power the kind of data centers OpenAI and other artificial intelligence companies need to power their AI models and services.</p>
<p>Altman is co-founder and CEO of OpenAI, which is valued at over $80 billion by private investors.  He said he sees nuclear energy as one of the best ways to solve the problem of growing demand for AI and the energy that powers that technology without relying on fossil fuels.  Microsoft co-founder Bill Gates and Amazon founder Jeff Bezos have also invested in nuclear power plants in recent years.</p>
<p>“I don’t see a way for us to get there without nuclear power,” Altman told CNBC in 2023.  “I mean, maybe we could get there just with solar and storage.  But from my perspective, I feel like this is most likely and the best way to get there.”</p>
<p>In an interview with CNBC on Thursday, Oklo CEO Jacob DeWitte confirmed that the corporate isn&#8217;t yet generating revenue and doesn&#8217;t currently have any nuclear power plants in use.  He said the corporate goals to commission its first plant in 2027.</p>
<p>Going the SPAC route is dangerous.  So-called reverse mergers became popular within the low-interest-rate days of 2020 and 2021, as technology valuations soared and investors sought growth reasonably than profit.  But the SPAC market collapsed in 2022 together with rising rates of interest and has not recovered.</p>
<p>AI-related firms, alternatively, are the brand new darlings of Wall Street.</p>
<p>“SPACs haven’t exactly performed the best in recent years.  The fact that we achieve the result here obviously depends on the work we have put in, but also on what we are building and also the fact that the market sees opportunities here,” said DeWitte, who co-founded the corporate in 2013 .  “I think it’s very promising in a lot of ways.” [the] Nuclear, AI, data center push and the energy transition.”</p>
<p>The company has experienced a series of regulatory setbacks.  In 2022, the U.S. Nuclear Regulatory Commission rejected Oklo&#39;s application for a reactor in Idaho.  The company is working on a brand new application that it doesn&#39;t plan to undergo the NRC until early next yr, DeWitte said, adding that it&#8217;s currently within the &#8220;pre-application phase&#8221; with the commission.</p>
<p>Altman got involved with Oklo when he was president of the startup incubator Y Combinator.  Oklo took part in this system in 2014 <a href="https://www.ycombinator.com/blog/jacob-dewitte-oklo-interview/" target="_blank" rel="noopener">previous meeting</a> between Altman and DeWitte.  In 2015, Altman invested in the corporate and have become chairman.</p>
<p>It&#39;s not Altman&#39;s only foray into nuclear energy or other infrastructure that might spur large-scale AI growth.</p>
<p>In 2021, Altman led a $500 million funding round for clean energy company Helion, which is working to develop and commercialize nuclear fusion.  Helion said in a single <a href="https://www.helionenergy.com/articles/announcing-500-million-fundraise/" target="_blank" rel="noopener">blog entry</a> At that time, the capital would begin its Polaris power demonstration generator, “which we expect will demonstrate net fusion power in 2024.”</p>
<p>Altman didn&#8217;t reply to a request for comment.</p>
<p>In recent years, Altman has also poured money into chip projects and investments that might help advance the AI ​​tools developed by OpenAI.</p>
<p>Shortly before his temporary ouster as OpenAI CEO in November, he was <a href="https://www.bloomberg.com/news/articles/2023-11-19/altman-sought-billions-for-ai-chip-venture-before-openai-ouster?embedded-checkout=true" target="_blank" rel="noopener">allegedly </a>is in search of billions of dollars for a chip company codenamed “Tigris” to eventually compete with <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-19">Nvidia<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>.</p>
<p>Altman invested in AI chip startup Rain Neuromorphics in 2018, based near OpenAI headquarters in San Francisco.  The next yr, OpenAI signed a letter of intent to spend $51 million on Rain&#39;s chips.  In December, the US forced a enterprise capital firm backed by Saudi Aramco to sell its shares in Rain.</p>
<p>DeWitte told CNBC that the info center represents &#8220;a pretty exciting opportunity.&#8221;</p>
<p>“What we’ve seen is that there’s a lot of interest in AI in particular,” he said.  “The AI ​​computing needs are significant.  It opens the door to many different approaches to the way people think about the design and development of AI infrastructure.”</p>
<p><strong>REGARD:</strong> Investing in the longer term of AI</p>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/107361037-17055870662024-01-18t102403z_838136397_rc2ak5a86bbx_rtrmadp_0_davos-meeting.jpeg?v=1705594949&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
	</channel>
</rss>
